2001 Data Treatment 
Veriheal
MAY 18, 2023
Nonetheless, guidelines pertaining to the use of cannabis-based treatments for chronic pain relief have been somewhat hazy…up until now. The team peered into the findings of numerous articles published between 2001 and 2019. Chronic pain —a condition that affects 50.2 million people in the U.S.
Veriheal
AUGUST 7, 2022
New data published in the Journal of Cannabis Research claims that almost one in two authorized medical cannabis patients in Canada managed to either completely stop or reduce their intake of controlled substances, such as alcohol and opioids , by using cannabis. As of 2020, the market was worth CAD $2.6 billion (USD $2 billion).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
MARCH 6, 2021
Oxaliplatin, the researchers said, “is a platinum-based chemotherapy widely used for the treatment of gastrointestinal (GI) malignancies.” This reduction was more significant in patients who received cannabis prior to treatment with oxaliplatin, suggesting a protective effect. A large prospective trial is planned.”.
Cannabis Law Report
NOVEMBER 17, 2021
The constitutional convention saw the campaign to reschedule psilocybin elevated to national headlines, and a week later British psychedelic company COMPASS Pathways released data from its pivotal Phase IIb trial with psilocybin, which demonstrated its efficacy in treatment-resistant depression.
Sensi Seeds
JANUARY 4, 2019
Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). Context of the Medicinal Cannabis Situation.
CannaTech
SEPTEMBER 16, 2018
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. Cannabis medicine presents itself as an intimidating option despite patients requesting it as a form of treatment. Changing Cannabis Conversations Worldwide. Education and Resources to Drive Medical Cannabis.
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe. Rick Doblin, Ph.D.,
Expert insights. Personalized for you.
98 
Let's personalize your content